AstraZeneca Plc continued to profit from its increasingly diverse portfolio of medicines in the third quarter while advancing a Covid-19 vaccine for the global population. In a call with reporters on 5 November, company executives said Phase 3 data for the vaccine could potentially be available this year. Trials were paused in September in order to investigate a safety event, but resumed at international sites thereafter.
